Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 28, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
This expert-led panel discussion, moderated by Scott Newsome, DO, will review new findings showing a significant and causative relationship between infection with Epstein Barr virus and the development of multiple sclerosis, and discuss the implications for patients, the health care providers who treat them, and the greater neurology community.
The research director and staff scientist at Cleveland Clinic’s Epilepsy Center detailed the clinical pre- and post-surgery benefits patients with epilepsy get from MR fingerprinting, a novel technology that uses conventional MRI scanners but can quantify multiple properties of tissue in a single scan, characterizing areas smaller than a single voxel in a fraction of the time.
The cognitive neurologist at the University of California, San Francisco discussed recently published data on the presence of cognitive post-acute sequelae of COVID-19, the need to legitimize these conditions, the hypothesis that understanding the clinical features associated with cognitive PASC may inform groups at greater risk and highlight possible underlying mechanisms.
Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Bridget A. Bagert, MD, MPH, director, Ochsner Multiple Sclerosis Center, and an investigator in the clinical study of an Epstein-Barr virus-targeted agent, ATA188 (Atara Biotherapeutics).
Biogen and Eisai announced an increase in enrollment to 1500, and that 18% percent of the Alzheimer disease treatment’s study participants are anticipated to be Black/African American and Latinx.
Recognize and celebrate the individuals who have achieved landmark successes within multiple sclerosis! Giants of Multiple Sclerosis™ is a premier neuroscience award that celebrates pioneers, innovators, and future generations of leaders who have been selected by their peers for their remarkable achievements in Multiple Sclerosis.